

***palliPHARM* Palliative Care Medicine Project and Reimbursement Funding Opportunity**

Regional, rural and remote Queensland pharmacies are eligible for a reimbursement payment of \$100 to stock the [Core Palliative Care Medicines List for Queensland Community Patients](#) (see Table 1).

This funding opportunity is the result Queensland Health's and the Pharmaceutical Society of Australia's commitment to support community-based end-of-life care in regional, rural, and remote parts of Queensland. Funding has been made available for pharmacies that service regional, rural, and remote communities consequent to the *palliPHARM* and PallConsult initiatives (for a summary of these initiatives see page over).

Your pharmacy may be eligible for a reimbursement payment of \$100 to stock ONE box of each of the FIVE core palliative care medicines. This payment is a single one-off payment limited to one per pharmacy.

Community Pharmacy Eligibility Criteria:

1. Community pharmacy must be in a Modified Monash Model (MMM) Category region MM2 to MM7. (Use the [Health Workforce Locator](#) to find out what MMM category region your pharmacy is located within)
2. Able to provide evidence to confirm current stock holdings or proof of purchase for ONE box of each of the five medicines in the [Core Palliative Care Medicines List for Queensland Community Patients](#).

Please note this MUST include one medicine from each of the five medicine categories as listed on Core Palliative Care Medicines list AND the stocked medicines should have adequate expiry dates. Evidence to be uploaded using the Eligibility and Payment Claim Form (see link below). Examples of proof may include:

- Photo or screenshot of the order submitted to your wholesaler
- Photo of the stock stored within your community pharmacy
- Report from point-of-sale system showing stock on hand

If your pharmacy meets the above criteria fill out the [palliPHARM Palliative Care Medicine Reimbursement Funding for Regional, Rural and Remote Community Pharmacies in Queensland: Eligibility and Payment Claim form](#) by scanning the QR Code below or copying the weblink into your internet browser:



Weblink: <https://www.surveymonkey.com/r/T7D7NJR>

This funding opportunity is only available until 15th June 2022.

For further information on the payment program
Email: pcam1007@psa.org.au

For information on the PallConsult & *palliPHARM* programs
Tel: 07 3338 9080
Email: pallipharm@health.qld.gov.au

Summary of the *palliPHARM* initiative

palliPHARM works with community pharmacists to ensure community-based palliative care patients and aged care residents have timely access to palliative care medicines, if needed.

Most Australians nominate home, whether that be a private house or a residential aged care facility (RACF), as their preferred place for end-of-life care. However, if end-of-life symptoms are not well controlled, this can lead to unnecessary suffering and unplanned hospital admissions.

To prevent such unwanted outcomes, all community-based palliative patients need rapid access to medicines to manage any emergent symptoms, thereby supporting people to die comfortably in the environment of their choice.

As part of the project, pharmacies are requested to stock at least one medicine from each of the five medicine categories included in the [Core Palliative Care Medicines List for Queensland Community Patients](#). These are low-cost medicines, and many pharmacies may already stock some or all of them. Pharmacies that stock these medicines are encouraged to sign up to the *palliPHARM* project by completing the [palliPHARM Letter of Intent](#).

To learn more about *palliPHARM*, read the [palliPHARM factsheet](#).

Table 1: Core Palliative Care Medicines List for Queensland Community Patients

Medicine Category	Medicines		Minimum Quantity to stock	Indication/(s) for use in terminal phase patients
	First Line	Second Line		
Analgesic (High potency opioid)	Morphine (sulfate or hydrochloride) 10mg/mL and/or 30mg/mL Injection	Fentanyl citrate 100µg/2mL Injection Hydromorphone 2mg/mL Injection	5 ampoules	Dyspnoea Pain
Anticholinergic	Hyoscine butylbromide 20mg/mL Injection	-	5 ampoules	Respiratory tract secretions
Antiemetic	Metoclopramide 10mg/2mL Injection	Haloperidol 5mg/mL Injection	10 ampoules	Nausea, vomiting
Antipsychotic	Haloperidol 5mg/mL Injection	-	10 ampoules	Agitation Nausea, vomiting Refractory distress
Anxiolytic	Clonazepam 1mg/mL Injection	Midazolam 5mg/mL Injection	5 or 10 ampoules	Agitation Dyspnoea Refractory distress
	Clonazepam 2.5mg/mL (0.1mg/drop) Oral Liquid		10mL bottle	Seizures

Summary of the PallConsult program

[PallConsult](#), has been designed to boost the ability of local healthcare teams to deliver patient-centred palliative care, especially in rural and remote parts of the State. Its goal is to enhance palliative and end-of-life care for all Queenslanders, particularly those living in the community, residential aged care facilities and regional and rural areas, by augmenting the care delivered by local clinicians.

[PallConsult](#) will support people to be cared for and, likely, to die in their place of choice and to reduce unwanted presentations to acute care facilities.

This [factsheet](#) explains more about the PallConsult project or you can visit the [PallConsult website](#) at www.pallconsult.com.au to view project resources.

Pharmacists can access a PallConsult palliative care advice hotline 24/7, 1300PALLDR* (1300 725 537) for advice on palliative care issues.

Palliative Care Resources & Education

Pharmacists are encouraged to visit the [palliPHARM microsite](http://www.psa.org.au/pallipharm/) (www.psa.org.au/pallipharm/), a website hosted by the Pharmaceutical Society of Australia with links to education opportunities, resources and content relevant to palliative care.